Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.

摘要: Novel vaccination approaches based on rational design of B- and T-cell epitopes - epitope-based vaccines are making progress in the clinical trial pipeline. The epitope-focused recombinant protein-based malaria vaccine (termed RTS,S) is a next-generation approach that successfully reached phase-III trials, will potentially become first commercial against human parasitic disease. Progress made methods such as DNA technology, advanced cell-culture techniques, immunoinformatics immunogens driving development these novel concepts. Synthetic proteins comprising both can be efficiently produced through modern biotechnology bioprocessing methods, enable induction large repertoires immune specificities. In particular, inclusion appropriate CD4+ increasingly considered key component to elicit robust responses, suggested by results coming from HIV-1 trials. silico strategies for under active address genetic variation pathogens several broadly protective "universal" influenza currently at different stages Other focus improving population coverage target populations rationally considering specificity prevalence HLA proteins, though proof-of-concept humans has not been demonstrated yet. Overall, we expect central part production process.